Eventide Healthcare & Life Sciences Fund C (ETCHX)
45.36
+0.20
(+0.44%)
USD |
Dec 31 2025
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 2.31% | 1.680B | 0.00% | 41.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -227.41M | 55.13% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Small Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Eventide |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
72
-273.45M
Peer Group Low
933.51M
Peer Group High
1 Year
% Rank:
78
-227.41M
-2.811B
Peer Group Low
341.98M
Peer Group High
3 Months
% Rank:
70
-603.80M
Peer Group Low
1.650B
Peer Group High
3 Years
% Rank:
69
-8.541B
Peer Group Low
312.13M
Peer Group High
6 Months
% Rank:
69
-1.426B
Peer Group Low
1.263B
Peer Group High
5 Years
% Rank:
65
-7.875B
Peer Group Low
2.983B
Peer Group High
YTD
% Rank:
--
--
Peer Group Low
--
Peer Group High
10 Years
% Rank:
5
-13.24B
Peer Group Low
5.532B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of January 01, 2026.
Asset Allocation
As of September 30, 2025.
| Type | % Net |
|---|---|
| Cash | 4.81% |
| Stock | 92.40% |
| Bond | 1.41% |
| Convertible | 0.00% |
| Preferred | 1.63% |
| Other | -0.24% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Insmed, Inc. | 6.18% | 174.04 | -0.03% |
| Mirum Pharmaceuticals, Inc. | 5.88% | 78.99 | 0.18% |
|
USD Cash
|
4.68% | -- | -- |
| Guardant Health, Inc. | 4.48% | 102.14 | 1.53% |
| Celcuity, Inc. | 4.00% | 99.74 | -0.18% |
| Scholar Rock Holding Corp. | 3.67% | 44.05 | 0.99% |
| Axsome Therapeutics, Inc. | 3.50% | 182.64 | 22.75% |
| Alnylam Pharmaceuticals, Inc. | 3.42% | 397.65 | 0.10% |
| iRhythm Technologies, Inc. | 2.85% | 177.44 | -0.63% |
| Kymera Therapeutics, Inc. | 2.71% | 77.81 | -0.40% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 1.10% |
| Administration Fee | 23.67K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | 0.00% |
| Maximum Redemption Fee | 1.00% |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 50.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks to provide long-term capital appreciation. The Fund will invest at least 80% of its net assets, plus borrowings for investment purposes, in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Small Cap Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Eventide |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (12-30-25) | 0.62% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 71 |
| Stock | |
| Weighted Average PE Ratio | 43.42 |
| Weighted Average Price to Sales Ratio | 19.84 |
| Weighted Average Price to Book Ratio | 12.19 |
| Weighted Median ROE | -327.4% |
| Weighted Median ROA | -28.00% |
| ROI (TTM) | -33.24% |
| Return on Investment (TTM) | -33.24% |
| Earning Yield | 0.0296 |
| LT Debt / Shareholders Equity | 2.454 |
| Number of Equity Holdings | 65 |
As of September 30, 2025
Growth Metrics
| EPS Growth (1Y) | 7.42% |
| EPS Growth (3Y) | 4.94% |
| EPS Growth (5Y) | 8.57% |
| Sales Growth (1Y) | 27.65% |
| Sales Growth (3Y) | 36.09% |
| Sales Growth (5Y) | 41.56% |
| Sales per Share Growth (1Y) | 79.68% |
| Sales per Share Growth (3Y) | 48.27% |
| Operating Cash Flow - Growth Rate (3Y) | 17.17% |
As of September 30, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:ETCHX", "name") |
| Broad Asset Class: =YCI("M:ETCHX", "broad_asset_class") |
| Broad Category: =YCI("M:ETCHX", "broad_category_group") |
| Prospectus Objective: =YCI("M:ETCHX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |